We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Improved Ebola IVD Tests Continue to Face Challenges

By LabMedica International staff writers
Posted on 13 Apr 2015
A new Ebolavirus test provides significant advantage over the current diagnostic pathway, yet there is little justification to establish permanent, advanced testing at expense of more pressing needs. More...


The new Ebolavirus test, Improved Ebola Diagnostic, developed by the UK’s Defence and Science Technology Laboratory (DSTL) is a step forward and provides significant advantage as it can be carried out at point-of-care (POC) and uses a much smaller sample of capillary blood. However, there remains a need for low-cost, POC testing devices that overcome the logistical and geopolitical obstacles presented by Sub-Saharan Africa, according to Andrew S. Thompson, PhD, senior analyst covering in vitro diagnostics (IVD) at research and consulting firm GlobalData (London, UK).

“By performing the test at the patient’s bedside, the risks of exposure, through transport to a laboratory, are minimized. It needs no specialist equipment and requires very little training, which reduces the diagnostic load on the pathology laboratory, freeing up capacity for confirmatory testing,” said Mr. Thompson.

“However, while the test was shown to be very successful in diagnosing patients admitted to hospital, and who were therefore symptomatic for Ebola, no such testing was carried out on asymptomatic patients in a non-hospital setting.” Furthermore, because viruses such as Ebola generally result in transient outbreaks in poverty-stricken regions, there is little justification to establish permanent, high-grade, molecular diagnostic testing if it comes at cost to more pressing and basic healthcare needs.

“The present Ebola outbreak is the largest known in history, but it is difficult to predict, once it subsides, if such repeated large-scale casualty events will occur again. In any case, Ebola is just one of many emerging, highly pathogenic viruses affecting Sub-Saharan Africa,” said Mr. Thompson, “For now, new tests such as DSTL’s Ebola lateral flow assay, based on long-established and mature technology, remain the best point-of-care testing for rare and emerging infectious diseases. However, in the longer term, these are likely to be overtaken by miniaturized nucleic acid-detection platforms, which can truly bring the gold standard of testing out of the laboratory.”

Related Links:

GlobalData



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The sample preparation instrument will streamline and simplify the workflow for the Co-Dx PCR MTB Test (Photo courtesy of Co-Diagnostics)

Sample Prep Instrument to Empower Decentralized PCR Testing for Tuberculosis

Tuberculosis remains the deadliest infectious disease worldwide despite being both treatable and curable when diagnosed early. A major barrier to timely diagnosis is that PCR-based TB testing is still... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.